Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMA3W2D)

Drug Name	XXB750 DMA3W2D

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

1 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Hypertension	DISLL965	BA00-BA04	Phase 2	[1]
------------------------------------------------------------------------------------

1 Phase 1 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Heart failure with preserved ejection fraction	DISESK0U	BD11.0	Phase 1	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05562934) A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT05328752) A Randomized, Participant- and Investigator-blinded, Sponsor Open-label, Placebo-controlled, Single and Multiple Dose Study to Investigate the Safety and Tolerability of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF). U.S.National Institutes of Health.